DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• DBV Technologies has a “Moderate Buy” consensus rating: Five of seven analysts recommend buying the stock, while one rates it a hold and one recommends selling. The average 12-month price target is $48.50.
• Institutional investors hold 71.74% of the company: Several funds increased or initiated positions during the first quarter, including Vivo Capital, ADAR1 Capital Management and Perceptive Advisors.
• Shares opened at $12.35, down 1.3%, with a 52-week range of $8.85 to $26.18. DBV is a clinical-stage biotech developing Viaskin, including its lead peanut-allergy treatment candidate, Viaskin Peanut.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $48.50.

A number of analysts recently issued reports on the company. Wall Street Zen downgraded DBV Technologies from a "hold" rating to a "sell" rating in a research report on Saturday, July 4th. Citizens Jmp upped their target price on shares of DBV Technologies from $47.00 to $55.00 and gave the company a "market outperform" rating in a research report on Tuesday, June 30th. HC Wainwright reaffirmed a "buy" rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Cantor Fitzgerald reiterated an "overweight" rating on shares of DBV Technologies in a research report on Thursday, September 10th. Finally, Weiss Ratings downgraded shares of DBV Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, July 17th.

Institutional Trading of DBV Technologies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DBVT. Vivo Capital LLC boosted its position in shares of DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company's stock worth $55,726,000 after buying an additional 205,943 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of DBV Technologies in the first quarter valued at $21,159,000. Perceptive Advisors LLC purchased a new stake in shares of DBV Technologies in the 1st quarter valued at $20,146,000. Atika Capital Management LLC raised its holdings in shares of DBV Technologies by 31.1% in the 1st quarter. Atika Capital Management LLC now owns 271,300 shares of the company's stock valued at $5,667,000 after buying an additional 64,419 shares during the period. Finally, Elmind Capital LP acquired a new position in DBV Technologies during the 1st quarter worth about $5,536,000. Hedge funds and other institutional investors own 71.74% of the company's stock.

DBV Technologies Stock Down 1.3%

NASDAQ:DBVT opened at $12.35 on Friday. DBV Technologies has a 52 week low of $8.85 and a 52 week high of $26.18. The company has a market capitalization of $776.57 million, a P/E ratio of -3.52 and a beta of -0.95. The stock's fifty day moving average is $13.86 and its two-hundred day moving average is $17.25.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company's lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies' primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.